Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-INN805
- Development stage
- Phase 1
- Lead developer
- FindCure Biosciences
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-INN805 is a therapeutic radiopharmaceutical developed by FindCure Biosciences (ZhongShan) Co., Ltd. It consists of the beta-emitting radioisotope Lutetium-177 (177Lu) conjugated to INN805, a ligand that specifically targets Fibroblast Activation Protein (FAP). FAP is a cell surface glycoprotein highly expressed in the cancer-associated fibroblasts (CAFs) of the tumor stroma in various malignant solid tumors, including head and neck cancer, thyroid cancer, non-small cell lung squamous cell carcinoma, breast cancer, and sarcoma, while showing minimal expression in normal tissues. Upon binding to FAP in the tumor microenvironment, the compound delivers localized ionizing radiation, inducing DNA damage and cell death in both the stromal and adjacent malignant cells. The drug is currently undergoing Phase 1 clinical evaluation to determine its safety, dosimetry, and preliminary efficacy in patients with advanced solid tumors.
- Other names
- 177Lu-INN805 Injection
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 177Lu-INN805.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-INN805.